Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reiter

Showing results (401-410 of 426) with videos related to

Pageof 43
Sort By:
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2010
Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptorAmy S Antipas, Laura C Blumberg, William H Brissette, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Journal of Medicinal Chemistry|January 5, 1996
Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH groupR P Robinson, L A Reiter, W E Barth, et al.
Journal of Medicinal Chemistry|March 29, 2018
Correction to Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH GroupRalph P Robinson, Lawrence A Reiter, Wayne E Barth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2014
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposalP Valent, K Sotlar, W R Sperr, et al.
Leukemia|February 5, 2015
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisM Arock, K Sotlar, C Akin, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 1999
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocketL A Reiter, J P Rizzi, J Pandit, et al.
Nature Biomedical Engineering|March 29, 2019
Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Nature Biomedical Engineering|April 25, 2019
Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Pageof 43

Showing results (401-410 of 426) with videos related to

Sort By:
Pageof 43
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2010
Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptorAmy S Antipas, Laura C Blumberg, William H Brissette, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Journal of Medicinal Chemistry|January 5, 1996
Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH groupR P Robinson, L A Reiter, W E Barth, et al.
Journal of Medicinal Chemistry|March 29, 2018
Correction to Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH GroupRalph P Robinson, Lawrence A Reiter, Wayne E Barth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 29, 2014
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposalP Valent, K Sotlar, W R Sperr, et al.
Leukemia|February 5, 2015
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisM Arock, K Sotlar, C Akin, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 1999
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocketL A Reiter, J P Rizzi, J Pandit, et al.
Nature Biomedical Engineering|March 29, 2019
Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Nature Biomedical Engineering|April 25, 2019
Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugsMatthew R Golder, Jenny Liu, Jannik N Andersen, et al.
Pageof 43